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 In mammals, the suprachiamatic nucleus (SCN) of the anterior 
hypothalamus acts as master circadian rhythm generator, which regulates 
the molecular organizations of clock oscillations residing in peripheral 
organs. Molecular circadian clock organization have evolved to adapt day 
and night environmental changes and to regulate daily physiological 
occurrences. And one of the important roles of circadian clock is to control 
daily metabolism in molecular and in systemic levels.  
 5’-AMP activated protein kinase, AMPK, is known as the key 
cellular energy sensor, which interacts with circadian clock to maintain 
cellular energetic status. AMPK is involved with various metabolic 
functions, such as glycolysis, gluconeogenesis and lipid metabolism. 
Therefore, AMPK has been a key target for developing therapeutic agents 
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to treat metabolic disorders. Metformin is known as the first-in class 
therapeutic choice for treatment of type 2 diabetes. It has been used since 
early 1950s, and growing mechanistic studies have identified AMPK as 
key modulating factor by metformin to decrease hyperglycemia and 
increase insulin sensitivity. Here, following the previous results of 
metformin’s effects on circadian oscillation, I have investigated effects 
metformin-derived novel chemical compound, H271, on circadian clock. 
Compared to metformin, I was able to find HL271 was much more potent 
on AMPK phosphorylation. Under ~1000x lower dosage concentration, 
HL271 displayed similar molecular effects as compared to metformin. 
HL271, also modulated molecular circadian clock by increasing 
degradation rates of PER2 and CYR1 and shortening of Per2 expression 
dose-dependently. Interestingly, HL271 did not appear to lower blood 
glucose level as compared to metformin, and the difference of 
physiological outcome demonstrated that HL271 may act differently in 
systemic level. 
 Omega-3 fatty acids (FA) are known as essential fatty acids, 
which mammals require for normal development. Although omega-3 FA 
is known to elicit health benefits such as improved inflammatory system 
and, retinal- and neural development, there are paucity of studies 
regarding the effects of omega-3 FA on circadian clock.  
 By utilizing a unique omega-3 FA animal model, fat-1 transgenic 
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mouse, which converts omega-6 FA to omega-3 FA endogenously, I have 
investigated effects of omega-3 FA on circadian oscillation. By cross-
breeding fat-1 TG mouse with Per2::luc KI mouse and created fat-
1/Per2::luc mouse. Fat-1/Per2:luc mouse displayed enhanced Per2 
expression in the peripheral tissues, including liver, kidney and 
submandibular gland. In Fat-1 TG mouse, clock mRNA levels were 
elevated in liver and kidney, however, clock gene expression in the 
hypothalamus only displayed shifting of period.  Molecular analysis 
revealed that in Fat-1 TG mouse, the core clock gene, BMAL1 was highly 
sumoylated and ubiquitinated eliciting enhanced proteosomal-mediated 
degradation and protein turnover. In accordance with the alteration of 
clock oscillation in the SCN, Fat-1 TG mouse displayed elongated period 
during free-running activities in constant darkness (DD) condition. 
Therefore in the present study, I investigated effects of omega-3 FA on 
circadian clock system and provided evidence for role of omega-3 FA on 
molecular circadian clock oscillation, and illustrated possible benefits of 
omega-3 FA influencing pronounced circadian oscillation which may yield 
longer life. 
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BACKGROUND AND PURPOSE 
1 
BACKGROUND 
1. Mammalian circadian clock
1-1. Circadian rhythm 
We live on a planet that is governed by the diurnal cycle, which is 
caused by rotation of the Earth consisting about 24-hours. This led to the 
evolution of internal biological clocks virtually in all living organisms to 
anticipate the changes in the environment (Lowery and Takahashi, 2004). 
The term “circadian” comes from the Latin circa, “around”, and diem or 
dies, “day”, meaning literally “approximately one day”.  Daily events 
ranging from sleep/wake cycle in humans to photosynthesis in plants 
represents the evolutionarily conserved adaptation to the environment 
that can be traced back to early life forms. The principal factor for 
synchronization between the environment and the internal rhythm is light. 
Light is a strong zeitgeber, which is a synchronizing agent capable of 
resetting a pacemaker or synchronizing a self-sustaining oscillation. For 
example, under conditions of steady environment, the period of the self-
sustaining oscillation conforms to that of the zeitgeber. Another features 
of rhythmic synchronization from environment is through temperature 
2 
compensation. Most of the biological systems in living organisms relies 
on the temperature, as the temporal oscillation of circadian rhythm is 
almost the same over a broad range of physiological temperature 
(Viaterna et al., 2001).  
1-2. Hierarchical organization of circadian clock system 
In mammals, light is mediated by special photo-receptors in our 
eyes in cells that are known as intrinsically photo-sensitive receptor 
ganglion cells (ipRGC). Photoresponse in the ipRGC integrate light 
information through retino-hypothalamic tract (RHT) and reaches 
suprachiasmatic nucleus (SCN) located in anterior hypothalamus and 
situated directly above the optic chiasm. SCN has been identified as the 
dominant circadian pacemaker responsible for regulating circadian 
rhythm. It is composed of over ~20,000 neurons, each of which is thought 
to contain a cell-autonomous circadian oscillator generating dynamic 
spatial and temporal coordination upon synchronization (Yamaguchi et al., 
2003). Rhythmic oscillation have been observed in cells and tissues 
throughout the body in mammals, and these rhythms persist in in vitro 
culture, demonstrating that non-SCN cells also contain endogenous 
circadian oscillators (Balsalobre et al., 1998, Yamazaki et al., 2000). 
Therefore, for biological clocks to be effective and functional in an 
3 
organized circadian system, this requires SCN control of peripheral 









Figure 1.  Hierarchical organization of circadian clock system. The 
master pacemaker encoding the mammalian clock resides within the SCN. 
Clock genes are expressed in other regions of the brain and in most of 
the peripheral tissues. Peripheral clocks are synchronized through 
humoral, nutrient, and autonomic wiring and that the cell-autonomous 
function of the clock is important in pathways involved in fuel storage and 
consumption. A hierarchical model indicates that all peripheral clocks are 












1-3. Coupling of central and peripheral clocks 
 The SCN controls peripheral clock oscillation through both 
sympathetic and parasympathetic pathways (Kalsbeek et al., 2010). 
Sympathetic innervation from the SCN to the liver results in daily rhythms 
of plasma glucose by direct influence of the rhythms of hepatic 
gluconeogenesis (Kalsbeek et al., 2004). Autonomic pathways from the 
SCN influence oscillators in the adrenal gland and liver, which 
sympathetic innervation modulates the sensitivity of the adrenal gland to 
adrenocorticotropic hormone (ACTH) and influencing glucocorticoid (GC) 
release (Buijs et al., 1999, Kalsbeek et al., 2010). GC is considered as a 
strong humoral entraining signals, since level of GC oscillates in the 
circadian manner and reaches almost all parts of the body. Independent 
of the SCN, local signaling pathways can also affect peripheral oscillators, 
such as body temperature, circulating GC and feeding-related cues 
(Albrecht, 2010). Body temperature can reset the circadian rhythm of liver, 
kidney, lung and fibroblasts (Abraham et al., 2010, Buhr et al., 2010). And 
also, food-related signals are able to produce circadian patterns and the 
change of feeding/fasting schedule can uncouple the phase relationship 
between the SCN and peripheral clocks, suggesting that changes in 
metabolic signaling can influence systemic regulation of circadian clock 




1-4. Molecular mechanism of the mammalian circadian 
clock 
 The cell-autonomous driven circadian rhythm arise from an 
autoregulatory negative-feedback transcriptional and translational 
network (Lowery and Takahashi, 2004). Two interlocking feedback loops 
generate molecular mechanism of the circadian clock in mammals, 
consisting of core loop involving the activators, Circadian Locomoter 
Output Cycles Kaput (CLOCK) and Brain and Muscle ARNT-Like protein 
1 (BMAL1) and their target gene Period (Per) 1-3, Cryptochrome (Cry) 1-
2, Rev-erbα and RAR-related orphan receptor α (RORα) whose gene 
products form a negative-feedback repressor complex. In addition to core 
transcriptional feedback loop, other feedback loop involving REV-ERBα 
and RORα that represses Bmal1 transcriptional leading an antiphase 
oscillation in Bmal1 gene expression stabilizing the circadian oscillation 
(Gallega and Virshup, 2007). Therefore, the ubiquitous, cell-autonomic 
clocks in central and peripheral oscillators carry similar mechanisms 












Figure 2.  Molecular bases of circadian system. The clock 
mechanism consists of two main parts: (1) a transcriptional-translational 
feedback loop (TTL) consisting of a positive and a negative limb and (2) 
oscillating post-translational modification of gene products in the TTL, 
which regulate degradation and nuclear localization of these proteins. The 
two transcription factors, CLOCK and BMAL1, bind to E-box on the 
promoter of clock-controlled genes, including Pers, Crys, Rev-erbα and 
Rorα. Translated PER and CRY proteins are post-translationally modified, 
accumulate in the cytoplasm and, then. Translocate to the nucleus to 
repress CLOCK:BMAL1 transcription activity. On the other hand, Rev-
erbα and Rorα regulates Bmal1 expressing through the binding of RRE in 














2. Circadian clock and metabolism 
2-1. Congruent relations between circadian rhythm and 
metabolism  
 The circadian system orchestrates the temporal organization of 
many aspects of physiological events, including metabolism. Circadian 
regulation of metabolic homeostasis is intimately linked and disruption of 
circadian rhythms can contribute to many metabolic diseases (Green et 
al., 2008). The importance of circadian clock function in metabolic 
regulation in the periphery has been observed in mice genetic models. 
Bmal1 knock-out (KO) mice, Bmal1-/-, exhibit complete loss of rhythmicity 
causing abolished oscillations in plasma glucose and triglyceride (Rudic 
et al., 2004). In addition, tissue-specific deletion of Bmal1 in liver or 
pancreas display altered blood glucose level resulting hypoglycemia 
during the fasting phase of the feeding cycle and eventually leads to 
diabetes (Marcheava et al., 2010, Sadacca et al., (2005). Cry1-/-Cry2-/- KO 
mice display salt-sensitive hypertension due to elevated plasma 
aldosterone and also hyperglycemia eventually leads to diabetes mellitus. 
(Doi et al., 2010). Mutations in Per2 results in altered lipid metabolism and 
lower body weight and appears to show increased urinary sodium 




2-2. Clock control of cellular metabolic process 
  The timing of metabolism can be influenced by the systemic cues 
of circadian system arising from the SCN or through local clocks. 
Temporal regulation of various metabolic pathways are regulated by 
circadian clock system. This regulation is achieved by controlling the 
expression of enzymes controlling the expression of rate-limiting steps of 
a metabolic pathway and by integrating proteins such as nutrient sensor 
with the clock machinery (Sahar and Sassone-Corsi, 2012). Recent 
development of genome-wide and microarray studies, it has been 
estimated that ~22-30% of the transcriptome has been shown to be under 
circadian regulation (Panda et al., 2002; Storch et al., 2002). Among the 
rhythmic genes identified, many carry a role in metabolic processes, 
including lipid metabolism, glycolysis and gluconeogenesis, oxidative 
phosphorylation and detoxification pathways (Green et al., 2008). Mostly, 
feedback system represented the communication between circadian 
clock and metabolism including AMP/ATP ratio sensors, glucose and fatty 
acid sensors and redox sensors.  
 




 The communication between circadian clock and metabolism, 
sensors affecting both systems include redox sensors, AMP/ATP ratio 
sensors, glucose and fatty acid sensors. Circadian clock controls the 
expression of NAD+ salvage pathway by controlling the expression of 
nicotinamide phosphoribosytransferase (NAMPT), a key rate-limiting 
enzyme in the NAD+ biosynthesis (Nakahata et al., 2009). And inhibition 
of NAMPT promotes oscillation of clock gene Per2 by releasing 
CLOCK:BMAL1 from suppression of nutrient sensor, Sirtuin 1 (SIRT1). In 
turn, the circadian transcription factor CLOCK binds to upregulate Nampt, 
thus completing a feedback look involving NAMPT/NAD+ (Nahakata et a., 
2009; Ramsey et al., 2009).  
 Glucose homeostasis involves GC and its receptors. Application 
of high glucose concentration to fibroblast cell culture leads to 
transcriptional repression of Per1, Per2, and Bmal1 genes leading 
synchronization of fibroblast clocks (Hirota et al., 2002). A recent study 
has demonstrated that Cry family interacts with GR and modulates 
glucose signaling by reducing GR activation potential for the expression 
of the phosphoenolpyruvate caboxykinase 1 (Pck1) gene which encodes  
rate-limiting enzyme in gluconeogenesis, PEPCK.  
 One measure of cellular metabolic status is the ratio between 
AMP and ATP. A major sensor for the AMP/ATP ration is adenosine 
monophosphate-dependent protein kinase (AMPK), which is activated 
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when AMP/ATP ratio is high during low cellular energy status (Carling et 
al., 2011). The activity of AMPK is involved in various circadian clock 
mechanisms. Once activated, AMPK directly phosphorylates CRY1, 
leading to destabilization and degradation by ubiquitin ligase, F-box 
leucine-rich-repeat protein 3 (FBXL3) (Lamia et al., 2009). In addition, 
AMPK phosphorylates of casein kinase 1ε (CK1ε) modulating PER2 
protein stability leading accelerated degradation (Um et al., 2007). 
Activation of AMPK also leads to increase of NAD+ level possibly 
modulating circadian gene expression indirectly through SIRT1 activation 
(Frescas et al., 2005). 
 
2-4. Circadian disturbance and metabolic diseases 
 Many aspects of metabolic physiology are known to occur at 
specific times each day, suggesting circadian disruption may lead to 
augmentation and progression of metabolic syndrome. Circadian 
disruption can be caused by rotating shift-work, frequent transmeridian 
flights and constant stress leading to de-synchronization of the various 
body clocks (Albrecht, 2012). Many clinical and epidemiological provides 
an evidence that confounding factors of circadian disruption is associated 
with obesity, diabetes, cardiovascular complications and neurological 
disorders (Laposky et al., 2007). Shift-work and sleep deprivation leads 
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to dampen rhythms in growth hormone and melatonin, reduce insulin 
sensitivity, and elevates circulating cholesterol (Spiegel et al., 2009). And 
these changes eventually leads to weight gain, obesity and development 
of metabolic syndromes. Chronic shift-work can also favor the 
development of mood disorders due to a misalignment of rhythms in body 
temperature, melatonin and sleep (Hasler et al., 2010). This association 
has been demonstrated in Clock gene mutated mouse model. These 
animal displayed metabolic problems and obesity and behavior 
comparable to bipolar disorder patients, such as hyperactivity and mania-
like behavior (Roybal et al., 2007). Jet lag is commonly caused by 
frequent transmeridian flights. Constant experience of jet lag induces de-
synchronization of circadian rhythm between SCN and the peripheral 
clocks inducing symptoms like, sleep disturbance, daytime sleepiness, 
decrease cognitive skills, indigestion, nausea and performance 
impairment (Cho et al., 2000). These symptoms are associated with 
accelerated cardiomyopathy and premature mortality and also 
neuroendocrine control of appetite and glucose control (Figure 3) (Spiegel 












Figure 3.  Circadian clock and diseases. Many aspects of metabolic 
physiology are known to occur at specific time of the day. Circadian 
disruption can be arise by continuous irregular lifestyle, constant jetlag 
and shiftwork leading sleep disorder, mood disorder and metabolic 
syndrome. This suggests a potential link between disruption of synchrony 
between periods of rest/activity with feeding/fasting and energy 
storage/utilization may be tied to dysregulation of not only metabolism and 




















3. Fatty acids 
3-1. Types of fatty acids 
 Fatty acids (FAs) are long-chain hydrocarbon molecules 
containing a carboxylic acid. FAs are usually derived from triglycerides or 
phospholipids and when they are not attached to other molecules, they 
are known as “free fatty acids”. Depending on the types of carbon-carbon 
bond, FAs can be classified as either saturated or unsaturated. FAs that 
contain no carbon-carbon double bonds are termed as saturated fatty 
acids (SFAs) and fatty acids carrying carbon-carbon double bonds are 
known as unsaturated and fatty (UFAs) acids with multiple sites of 
unsaturation are termed polyunsaturated fatty acids (PUFAs). The 
number of carbon atoms followed by the number of sites of carbon-carbon 
double bond designates the numeric FAs. FAs carry important functions 
in our body serving as building blocks of cellular membrane, source of 
fuel and act as a second messenger to maintain physiological 
homeostasis. In class of PUFAs, essential fatty acids are required by the 
human body development but cannot be made from other substrates, and 
therefore must be obtained from diet. Mammals including humans lack 
the ability to introduce double bonds in fatty acids beyond carbon 9 and 
10 from the carboxylic acid, hence Omega-6 linolenic acid (LA) and the 
omega-3 α-linolenic acid (ALA) are essential for humans in the diet. In 
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addition longer-chain omega-3 FAs LA and ALA converts into 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are, 
which conversion is limited in humans. The main physiological 
requirement for omega-6 and omega-3 FAs is associated with arachidonic 
acid. Presence of arachidonic acid play a vital role in cell signaling by 
acting as a major precursor of prostaglandins, leukotrienes, and 
anandamides. (Sanders and Emery, 2003 from wiki). Dietary source of 
omega-3 and omega-6 can be found in fish, flaxseed, hemp seed, soya 
oil, canola oil, sunflower seed and walnuts. In turn, fish is the main source 
of the omega-3 EPA and DHA which has been shown to provide many 
health benefits (Figure 4). 
 
3-2. Functions of fatty acids 
 Fat has traditionally been regarded as important source fuel, 
nutrients and source of essential fatty acids. FAs have been increasingly 
recognized as major biological regulators and varying intake of dietary 
FAs leads to changes in cell membrane structure and functions. In 
addition, FAs have differential effects on the production of cytokines, 
chemotaxis, and other factors relating to the immunological response 
(Deckelbaum et al., 2006). Some important biological functions of FAs  
includes, modulating pathways of blood coagulation, influence sterol 









Figure 4.  Types of fatty acids. Fatty acids are made up of carbon and 
hydrogen molecules. There are three types of fatty acids: saturated, 
monounsaturated and polyunsaturated. The basic difference between 
each of these are the number of carbon atoms or without two hydrogen 
atoms bonded to them. In a saturated fatty acids, each carbon atom has 
bonded with two hydrogen atoms. In a monounsaturated fatty acids, on 
pair of carbon atoms forms a double bond with each other that replaces 
the bon each would have with one hydrogen atom. A polyunsaturated fatty 
acid has two or more carbon pairs that have bonded together rather than 












receptor expression (Clandinin et al., 1991). Therefore, many of the 
effects of FAs in both cell biology and human health and disease relate to 
their abilities to regulate gene expression and subsequent downstream 
events.  
 
3-3. Benefits of omega-3 fatty acids 
 Increasing clinical and epidemiological studies demonstrates that 
increased omega-3 FAs consumption ameliorates or decrease the risk of 
a variety of diseases. Omega-3 FAs have shown definite roles in cognitive 
development and learning, visual function, the immune-inflammatory 
response, pregnancy, cardiovascular disease and cancer (Seo et al., 
2005). Distinct capacities of omega-3 FAs appears to modulate both 
cellular metabolic functions and gene expression. Their longer chain 
length, high number of double bonds and the presence of the first double 
bond gives omega-3 FAs distinct and unique properties compare to 
common omega-6 and omega-9. Overall, the positive effects of omega-3 
FAs on health relates to inhibition of eicosanoid pathways, leading 
alteration of inflammatory response, modulation of molecules or enzymes 
associated with various signaling pathways involving normal and 




 Because of the abilities of omega-3 to modulate metabolic 
pathways and suppress the gene expression related to lipid metabolism, 
it is being considered as therapeutic agents in dyslipidemia, various 
metabolic syndromes, type 2 diabetes and steatohepatitis (Deckelbaum 
et al., 2006). Omega-3 FAs, in particular EPA and DHA, have been shown 
to have similar regulatory effects as glitazones, a member of the 
thiazolidinedione drugs, on a large number of related pathways. Similar 
to glitazones, omega-3 FAs act as potent agonist for peroxisome 
proliferator-activated receptor γ (PPARγ) and have been used for 
treatment of a variety of lipid-related disorders. In addition, omega-3 FAs 
suppress large number of inflammatory proteins and in enhancing gene 
expression and activity of a large number of transcription factors that 
would help to ameliorate adverse pathways related to obesity, metabolic 
syndromes and type 2 diabetes. Dietary consumption of omega-3 FAs 
have shown to reduce risk of cardiovascular diseases by diminishing key 
contributors (Figure 5) (Li et al., 2004). 
 
3-4. Fat-1 transgenic mice: a novel animal model for 
omega-3 research 
 Dietary supplementation has been principal method to modify 
tissue nutrient composition in animal studies. However, feeding animals 








Figure 5.  Benefits of omega-3 fatty acids. Not only omega-3 is 
required for proper body development and functions, but also they deliver 
large health benefits. Omega-3 can lower elevated triglyceride levels and 
decrease risk of heart disease. And also provides beneficial effect on 
bipolar disorder and reduce mania-like behavior and depression. In 
addition, several lines of evidence provides omega-3 can reduce the 
incidence of sudden cardiac arrest, and reduce the total mortality and 












many confounding factors between experimental groups. Although the 
total energy can be examined with precise measurement of dietary intake, 
it is difficult to make all the dietary supplements to be identical between 
the diets. For example, currently there are no pure omega-3 and omega-
6 FAs available for animal diet. Generally, diet consisting of increased 
amounts of fish oil, plant seeds and vegetable oils have been used to 
provide omega-3 and omega-6 FAs. However, theses FAs are derived 
from different natural sources and may contain other unwanted bioactive 
compounds that may affect functions of omega-3 and omega-6. Therefore, 
inevitable differences between the diets act as confounding factors in 
nutritional studies and may contribute to inconsistent or conflicting results.  
 To overcome this experimental dilemma, groups of scientists have 
generated a transgenic (TG) mouse capable of converting omega-6 to 
omega-3 FAs. Mammals cannot convert omega-6 to omega-3 FAs 
because they lack the enzyme responsible for this conversion. However, 
by inserting fat-1 gene from Caenohabditis elegans, which encodes an 
omega-3 fatty acid desaturase that can introduce double bond into 
omega-6 FAs, by microinjection into fertilized eggs led to creation of novel 
transgenic mouse lines (Kang et al., 2004). As result, fat-1 TG mouse 
were capable of producing omega-3 FAs from omega-6 FAs, resulting in 
enrichment of omega-3 FAs in virtually all organs and tissues without the 
need of dietary omega-3 supplementation (Kang et al., 2004). Therefore, 
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the use of the fat-1 TG mice allowed scientists to overcome complications 
of conventional diet supplementation and concede with well-controlled 
studies (Figure 6). 
 
3-5. Interaction between fatty acids and circadian clock 
Fatty acid (FA) metabolism is influenced by daily fluctuations in 
activity and nutritional studies where during periods of intermittent fasting 
leads to increased FAs oxidation rates. The whole body FA metabolism 
can be compromised by manipulation of dietary nutrients quantities and 
qualities as well as timing of the meals throughout the 24 h period (Bray 
and Young, 2011). Observation of the time-dependent oscillation of FA 
metabolism have led to external environmental influences principally drive 
daily rhythms of FA metabolism by associated oscillations in circulating 
nutrients and metabolically relevant neural and hormonal inputs. Recent 
studies have demonstrated that mice fed with high fat diet (HFD) 
developed disrupted behavior circadian rhythms (Kohsaka et al., 2007). 
Mice subjected to HFD led to altered rhythms in core clock gene transcript 
expression and in clock target genes involved in metabolic homeostasis 
by delaying circadian expression of adiponectin signaling in the liver 
(Barnea et al., 2009). In addition, female mice fed with HFD for 6 wks did 
not show increased diurnal food intake, but did developed obesity, 
hyperlipidemia and hyperglycemia (Yanagihara et al.,2006). Overall, 
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feeding mice with high-fat diet could lead to disruptions in normal 










Figure 6.  Generation of fat-1 TG mice. The fat-1 gene of C. elegans 
encodes an n-3 fatty-acid desaturase enzyme that converts omega-6 to 
omega-3 and which is absent in most animals, including mammals. 
Modified Fat-1 gene encoding this protein by optimization of codon usage 
for mammalian cells and coupled to chicken beta-actin promoter. The 
expression vector is microinjected into fertilized eggs to produce 
















 With rising population of patients holding metabolic diseases, 
such as obesity and diabetes mellitus, it is becoming an epidemic issue 
worldwide. Since, circadian clock and metabolic system is tightly 
integrated systematically, the manipulation of circadian clock oscillation 
has been a new way of approach to treat metabolic diseases. In this 
regards, the present study aims to elucidate circadian clock regulation of 
metabolism as following: 
 
1. To investigate effects of metformin, the first-line of drug for type 2 
diabetes treatment, and metformin-derived novel chemical 
compound, HL271 on molecular oscillation of circadian clock and 
clock-controlled metabolic regulator. 
2. To investigate the effects of omega-3 fatty acids on circadian 
oscillation by utilizing novel transgenic animal model, fat-1 TG 
mouse.  
 









Effects of metformin and metformin-
derived novel chemical compound, 





 Self-sustaining circadian clock regulates daily physiological and 
metabolic events. Cell-autonomous clocks regulate metabolism by 
interacting with various factors responsible for metabolic homeostasis. 
For example, 5’-AMP activated protein kinase, AMPK, is known as the 
key cellular energy sensor, which interacts with circadian clock to maintain 
cellular energetic status. AMPK is involved with various metabolic 
functions, such as glycolysis, gluconeogenesis and lipid metabolism. 
Therefore, AMPK has been a key target for developing therapeutic agents 
to treat metabolic disorders. Metformin is known as the first-in class 
therapeutic choice for treatment of type 2 diabetes. It has been used since 
early 1950s, and growing mechanistic studies have identified AMPK as 
key modulating factor by metformin to decrease hyperglycemia and 
increase insulin sensitivity. Here, following the previous results of 
metformin’s effects on circadian oscillation, I have investigated effects 
metformin-derived novel chemical compound, H271, on circadian clock. 
Compared to metformin, I was able to find HL271 was much more potent 
on AMPK phosphorylation. Under ~1000x lower dosage concentration, 
HL271 displayed similar molecular effects as compare to metformin. 
HL271, also modulated molecular circadian clock by increasing 
degradation rates of PER2 and CYR1 and shortening of Per2 expression 
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dose-dependently. Interestingly, HL271 did not appeared to lower blood 
glucose level as compared to metformin, and the difference of 
physiological outcome demonstrated that HL271 may act differently in 
systemic level.  





 Cell-autonomous endogenous circadian clocks drive daily 
physiological and behavioral rhythms with a period of about 24 h (Reppert 
and Weaver, 2002). The SCN is the master circadian clock that 
synchronizes intrinsic clocks located throughout the peripheral organs of 
mammals (Froy, 2010). The timing of circadian clocks in peripheral organs 
can be reset by external cues, such as food intake and activity (Schibler, 
2005), indicating that metabolic cues can provide important feedback that 
organizes peripheral clock timing. 
 Molecular circadian clocks in mammals are driven by 
transcriptional-translational feedback loops, in which heterodimers of the 
proteins circadian locomoter output cycle kaput (CLOCK) and brain and 
muscle ARNT-like 1 (BMAL1) initiate the transcription of clock-controlled 
genes such as periods (Per1, Per2, and Per3), cryptochromes (Cry1 and 
Cry2), Rev-erbα, and RORα. The competitive binding of Rev-erbα and 
RORα to a ROR responsive element (RORE) transcriptionally fine-tunes 
the circadian clock oscillation of Bmal1 (Yagita et al., 2001; Mohawk et al., 
2012).  
 5’-Adenosine monophosphate (AMP)-activated kinase (AMPK) is 
a primary sensor of cellular energy and nutrient status in eukaryotic cells 
(Hardie, 2014). This enzyme generally senses changes in the AMP:ATP 
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ratio and is activated under conditions of low cellular energy. The kinase 
activity at the Thr172 phosphorylation site of the AMPK-α1 catalytic 
subunit phosphorylates downstream factors, switching the cell from a 
catabolic to an anabolic state and generating ATP (Hardie, 2014). AMPK 
activity is also involved in the molecular machinery of the cell’s circadian 
clock. Activation of AMPK was shown to regulate the direct 
phosphorylation of CRY1 at the Ser71 residue and partly at Ser280, 
leading to degradation by F-box and leucine-rich repeat protein 3 (FBXL3) 
(Lamia et al., 2009; Jordan et al., 2013). In addition, activated AMPK 
phosphorylates casein kinase I ε (CKIε) to promote the proteosomal-
dependent degradation of PER2 protein (Um et al., 2007). Thus, AMPK 
has been known to be a key link between circadian rhythm and cellular 
energy metabolism.  
 Metformin, one of the most widely prescribed drugs to treat 
patients with type 2 diabetes, was shown to phosphorylate AMPK in 
primary hepatocytes, lowering serum glucose concentration partly by 
reducing net hepatic glucose production (Zhou et al., 2001). 
Pharmacologically, metformin was found to inhibit the electron transport 
chain in mitochondria, specifically inhibiting complex I and increasing the 
AMP:ATP ratio, thus further activating AMPK (Fortez et al., 2014; Viollet 
et al., 2012). Metformin was shown to have tissue-specific effects on 
metabolic processes of circadian clocks (Barnea et al., 2012), but its 
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detailed physiological and molecular effects on these processes are still 
not well-understood. Although AMPK is activated by a wide range of 
physiological concentrations of metformin (He et al., 2015), the 
associations between the effects of metformin on the circadian clock and 
AMPK activation and its glucose-lowering effects remain unclear.   
 Based on the biguanide structure of metformin, Hanall 
Biopharmaceuticals recently developed HL271 as a next-generation anti-
hyperglycemic agent (Figure 7). In present study, I investigated the effects 
of HL271 with those of metformin on the circadian clock and the metabolic 
system. From the investigation, I demonstrate that HL271 affected AMPK 
phosphorylation, circadian clock oscillations and clock expression, and 
degradation similar to metformin, but much potently. I also provide that 
the net systemic effects of these two agents on glucose lowering and lipid 
metabolism differed markedly, suggesting that the biguanide-derived 




Materials and methods 
 
Cell culture and transfection 
 NIH3T3, HepG2, and wild-type mouse embryonic fibroblast (MEF) 
cells were cultured and maintained in Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin (PS) at 37°C in a humidified 
atmosphere containing 5% CO2. One day after seeding, cells were 
transfected with LipofectAMIN Plus (Invitrogen), lysed, and subjected to 
western blot or mRNA analysis. 
 
Western blot analysis 
 Cells were harvested in 4X sodium dodecyl sulfate (SDS) sample 
buffer (200 mM Tris [pH 6.8], 8% SDS, 40% glycerol, 400 mM β-
mercaptoethanol [Sigma], 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF, and 
1× protease inhibitor cocktail [Roche]). Whole-cell extracts were resolved 
on 8% SDS-polyacrylamide gels and transferred to polyvinylidene 
difluoride membranes (Immobilon P; Millipore). The membranes were 
incubated with anti-AMPKα, anti-phospho-AMPK (Thr172) (Cell Signaling 
Technology), anti-Flag M2 (Sigma), and anti-V5 (Invitrogen) antibodies. 
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The immune complexes were visualized with an ECL detection kit (Pierce) 
(Lee et al., 2007).  
 
Quantitative real-time PCR analysis 
 qPCR analysis was performed as described (Chung et al., 2014). 
Total RNAs were extracted from cells by using the guanidine thiocyanate 
method (TRIZOL; Life Technologies Inc.). A 2 μg aliquot of RNA was 
reverse-transcribed using Moloney murine leukemia virus reverse 
transcriptase (Promega). The cDNA was PCR amplified by Chromo4 DNA 
Engine (BioRad), and expression was quantified by SYBR green I real-
time analysis. The levels of expression of all genes were normalized to 
that of gluceraldehyde-3-phosphate dehydrogenase (GAPDH). The 
primers used for real-time PCR were as follows: mG6PD, 5’-
CAGCGGCAACTAAACTCAGA-3’(forward) and 5’-TTCCCTCAGGATC 
CACAC-3’ (reverse);mPck1,5’-GTGCTGGAGTGGATGTTCGG-3’  (forw 
ard) and 5’-CTGCTGATTCTCTGTTTCAGG-3’(reverse); hG6Pase, 5’-
AGAATCATCGTGGATGTAGACTCT-3’ (forward) and 5’-GCTTG GTG 
GTGATTGCTCTGCTA TG-3’ (reverse); hPck1, 5’-CGGTCAATA 
AACCATGTTCTGA-3’ (forward) and 5’-ACG CGGACTTTGATT 
CTGTATT-3’ (reverse); and GAPDH, 5’-CATGGCCTTC CGTGTTCCTA-
3’ (forward) and 5’-AGTTCTTCCACCACTTGCGTCC-3’ (reverse)  
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(Fortez et al., 2010).  
 
Recording of real-time luminescence  
 Wild-type MEFs were plated at 4 × 106 cells per dish in 35 mm 
dishes the day before monitoring luminescence. The cells were 
transduced with adenoviral Per2 promoter construct, as described 
(Cheon et al., 2013). Two hours before recording, the cells were treated 
with 1 μM dexamethasone (Sigma); at zero time, the medium was 
replaced with 2 mL of cultured medium (DMEM, supplemented with 10% 
FBS, 1% PS, and 0.1 mM luciferin [Promega], and containing DMSO 
[control], metformin, HL271, or HL271IA, an inactive compound). 
Bioluminescence was measured with a dish-type luminometer (AB-2500; 
ATTO Co.) at 36°C in a humidified atmosphere containing 5% CO2. 
 
Animal diet and housing 
 Mice were housed individually in a sound-proof isolated room in a 
conventional animal facility at a constant temperature (22–23°C) and 
humidity (50 ± 10%). Illumination for the LD cycle was provided by 32 W 
cool white fluorescence bulbs, with a measured light intensity of 200–250 
lux at the bottom of each cage. Lights were turned on at 08:00 and off at 
20:00 (L:D = 12 h:12 h). To generate diet-induced obese mice, wild-type 
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C57/BL/6J mice were fed ad libitum with a high-fat diet (HFD, with 60% 
kcal from fat; D12492, Research Diets) for 5 weeks. As a control group, 
mice were fed a normal diet (ND, with 12% kcal from fat; Purina 5001, 
Lab Diet). All animal experiments were performed according to the 
guidelines of the Laboratory Animal Centers at Seoul National University 
and DGIST. 
 
Drug administration  
 Diet-induced obese mice were orally administered with HL271 (10 
mg/kg or 30 mg/kg), diluted in drinking water, every morning at 09:30 for 
4–5 weeks. Negative control mice were administered drinking water alone, 
and positive control mice were administered metformin (400 mg/kg) in 
drinking water.   
 
Body composition and metabolic parameter analysis 
 The body weight and fat mass composition of mice were 
measured using a quantitative magnetic resonance whole-body 
composition analyzer (EchoMRI, Echo Medical Systems). Mice were 
starved for 12 h, and blood samples were drawn. Plasma insulin 
concentrations were measured using Ultra-Sensitive Mouse Insulin 
ELISA (Crystal Chem, Inc.), and plasma glucose concentrations were 
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measured by the Accu-Check® Performance kit (Roche). Total 
cholesterol, HDL, VLDL, and triglyceride concentrations were measured 
using the CR-3000 apparatus (CallegrariTM), according to the 
manufacturer’s protocols.  
 
Statistical analysis 
 All statistical analyses were performed using GraphPad PRISM 
software (GraphPad Prism Software Inc.). Between-group comparisons 
were assessed by one-way ANOVA, followed by post-hoc Tukey’s test. 
All values are expressed as the mean ± SEM, with statistical significance 





HL271 potently phosphorylates AMPK in a dose- and time- 
dependent manner 
 To determine whether HL271 phosphorylates AMPK like 
metformin, I assess AMPK phosphorylation level utilizing NIH 3T3, mouse 
firbroblast cells. HL271 dose-dependently phosphorylated AMPK under 
~1000x lower dosage as compared to metformin (Figure 8A and B). By 
contrast, HL271IA, an inactive form of HL271 used as a negative control, 
did not alter the phosphorylation of AMPK at several concentrations, 
indicating the specificity of HL271 on AMPK phosphorylation (Figure 8C). 
A time-course experiment showed that HL271, at a much lower 
concentration (10 μM), induced AMPK phosphorylation 4 h faster than 
metformin (Figure 9). Based on these dose- and time-dependent effects, 
10 μM HL271 and 2 mM metformin were used as positive controls in 
subsequent experiments. (Figure 10) Therefore, comparing between 
HL271 and metformin, I provide an evidence that HL271 under potent 
dosage, phosphorylated AMPK dose- and time- dependently.  
 




 To determine whether HL271 and metformin regulate clock gene 
expression in similar manner I have investigated the effects of HL271 on 
mPer2 promoter-driven destabilized luciferase activity in real-time were 
analyzed. Because metformin was shown to affect mPer2 oscillation (Um 
et al., 2007), MEFs stably expressing a mPer2-dsLuc construct were 
treated with metformin, HL271, or HL271IA. Consistent with previous 
findings (Um et al., 2007), metformin shortened the period and dampened 
the amplitude of mPer2-Luc expression in a dose-dependent manner 
(Figure 11A). HL271 showed similar activities, but at much lower 
concentrations than metformin (Figure 11B). By contrast, inactive 
HL271IA did not alter the period or amplitude of mPer2-dsLuc oscillation 
(Figure 11B-D).  
 
HL271 induces PER2 and CRY1 protein degradation 
 In previous studies, metformin was shown to degrade PER2 and 
CRY1 proteins, from the result of AMPK phosphorylation (Um et al., 2007; 
Lamia et al., 2009). To determine whether the effects of HL271 of the 
period and amplitude of mPer2 expression were due to an increased rate 
of molecular clock turnover, I have measured the degradation levels of 
PER2 and CRY1 proteins in cells treated with HL27. NIH3T3 transfected 
with V5-tagged PER2 (PER2-V5) or FLAG-tagged CRY1 (FLAG-CRY1) 
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were treated with metformin, HL271, or HL271IA in the presence of 
cycloheximide, an inhibitor of protein synthesis. I was able to find PER2 
and CRY1 protein degradation were more rapid in HL271 than in 
metformin treated cells (Figure 12A and B), whereas the inactive 
compound HL271IA had no effect on PER2 or CRY1 degradation. To 
further determine whether the degradation of these proteins is 
proteasome-dependent, I have repeated the experiment in the presence 
of the proteasome inhibitor MG132, together with cycloheximide. Neither 
metformin nor HL271 inhibited the degradation of PER2 and CRY1 
proteins (Figure 13 A and B). Taken together, these results indicate that 
HL271, like metformin, induced the degradation of PER2 and CRY1, 
probably affecting the amplitude and/or period of cellular oscillation 
(Figure 11).   
 
HL271 does not reduce body weight, blood glucose, or insulin level 
in diet-induced obese mice  
 Since metformin is used clinically as an anti-hyperglycemic and 
anti-diabetic agent, I have created diet-induced obese mice, an animal 
model of human type 3 diabetes, and investigated the effects of HL271 
on food intake and body weight. HFD-fed mice were orally administered 
metformin (400 mg/kg) or HL271 (10 and 30 mg/kg) dissolved in drinking 
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water for 4 weeks, and their daily food intake and total body weight were 
measured. A control group fed a normal diet (ND) displayed higher food 
intake than the HFD-fed group, but there were no differences in daily food 
intake between mice administered metformin (400 mg/kg) and HL271 (10 
and 30 mg/kg) (Figure 14A). Although metformin treatment resulted in a 
significant reduction in body weight gain, I found out that body weight gain 
in HL271-treated mice was the same as that of mice fed a ND and HFD-
fed mice (Figure 14B).  
 The major physiological effects of metformin is to lower blood 
glucose level in diabetic patients. Therefore, to assess the anti-
hyperglycemic effects of HL271, I have measured blood-glucose and 
insulin levels after a 12 h fast at 0, 2, and 4 weeks. Mice-treated with 
metformin showed significant reductions in blood-glucose and insulin 
levels compared with mice fed a ND (Figure 14C and D). Surprisingly, 
mice fed both 10 and 30 mg/kg HL271 showed no reductions in blood-
glucose and insulin levels (Figure 14 C and D).  
 
Different effects of metformin and HL271 on gluconeogenic gene 
expression in HepG2 cells and in wild-type mouse liver  
 To further investigate the differences in glucose-lowering effects 
between metformin and HL271, I have investigated the expression of 
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G6pase and Pck1 mRNAs were assayed in HepG2 cells, human liver 
hepatocellular carcinoma cell-line. Although treatment with 2 mM 
metformin decreased the levels of G6pase and Pck1 mRNAs, 10 μM 
HL271 had no effect (Figure 15A and B). The effects of HL271 on 
circadian expression of G6pase and Pck1 in vivo, I have interperitoneally 
injected metformin (500 mg/kg) or HL271 (100 mg/kg) into wild-type mice 
and liver tissues were collected every 6 h for 24 h to analyze G6pase and 
Pck1 expression. Liver G6pase did not display circadian oscillations in the 
three groups. By contrast, liver Pck1 expression peaked at CT2400, just 
before lights-on, and was minimal between CT 0600 and CT 1200, 
showing mild circadian oscillation (Figure 15C and D). Compared with 
control mice, the levels of G6pase and Pck1 were significantly reduced in 
mice injected with metformin (500 mg/kg), but not HL271 (100 mg/kg). 
Taken together, I was able to find that metformin reduced the blood-
glucose level partly by reducing the expression of the key gluconeogenic 
genes, G6pase and Pck1, in liver. By contrast, HL271 did not repress 
G6pase and Pck1 expression in the liver, with no net changes in blood-
glucose levels. 
 
HL271 does not alter levels of lipids and metabolites in diet-induced 
obese mice 
 Since metformin is also involved in lipid metabolism, the effects of 
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metformin and HL271 on fat mass and cholesterol and triglyceride levels 
were compared in diet-induced obese mice. Mice treated with metformin 
displayed decrease of total fat mass, however fat mass levels were not 
significantly changed in HL271 treated mice (Figure 16). In addition, 
following the metformin (400 mg/kg) treatment significantly reduced total 
fat mass, including epidermal fat and white adipose tissues, but not brown 
adipose tissue (Figure 17). Metformin also reduced LDL, but not HDL, 
levels , as well as total cholesterol and triglycerides, in liver and muscles. 
Neither concentration of HL271 (10 and 30 mg/kg) had any effects on total 
fat mass, organ-specific fat mass, and cholesterol levels, including HDL 
and LDL, or on liver- and muscle-specific triglyceride levels (Figure 17). 
Therefore, although HL271 has molecular effects similar to metformin on 
AMPK phosphorylation and circadian clock gene modifications, the net 
systemic effects of HL271 on glucose lowering and lipid metabolism 














Figure 7. Chemical structure of metformin, HL271 and HL271IA. 
Chemical structures and molecular weight of metformin, HL271 and 
HL271IA. Based on the biguanide structure of metformin, which molecular 
weight consist of 129.164 g/mol, HL271 contain pyrolidine and benzyl 
trifluoromethyl group weighting 375.35 g/mol. HL271IA contains 



















Figure 8. Dose-dependent AMPK phosphorylation by metformin and 
HL271. (A) Detection of AMPKα1 Thr172 phosphorylation in NIH3T3 cells 
after treatment for 4 h with 0.125, 0.25, 0.5, 1, 2, and 4 mM metformin, 
and (B and C) 0.31, 0.62, 1.25, 2.5, 5, and 10 μM HL271 and HL271IA. 
Phosphorylated AMPK is normalized by the endogenous AMPK and 
displayed in bar graph. Vales are the mean ± standard error of the mean 
(SEM) of three or four independent experiments performed in triplicates 
























Figure 9. Time-dependent AMPK phosphorylation by metformin and 
HL271. Time-dependent measurement of AMPKα1 Thr 172 
phosphorylation level after treatment with metformin (2 mM) or HL271 (10 
uM) in NIH3T3 cells. 0, 2, 4 and 8 hours after metformin and HL271 
treatment, cells were harvested proceeded to western blotting. 
Phosphorylated AMPK level were analyzed by normalization between 

























Figure 10.  AMPK phosphorylation by HL271 under ~500x lower 
concentration. Comparison and quantification of AMPKα1 Thr172 
phosphorylation level normalized relative to non-phosphorylated AMPK 
level after treatment for 4 h with metformin (2 mM), HL271 (10 μM), or 
HL271IA (10 μM). Each number represents the mean ± SEM values of 
three independent experiments, with each experiment performed in 
triplicate and compared by one-way ANOVA, followed by Tukey’s test. *P 

























Figure 11.  Dose-dependent effects of metformin and HL271 on Per2 
expression. Real-time luminescence recording of WT MEFs transduced 
with an adenoviral Per2 promoter-driven luciferase construct. Treatments 
with (A) 1, 2, and 4 mM metformin, (B) 2.5, 5, and 10 μM HL271, and (C) 
2.5, 5, and 10 μM HL271IA. (D) Luminescence recordings of cells treated 
with DMSO (negative control), metformin (2 mM), HL271 (10 μM), and 
HL271IA (10 μM) after dexamethasone (1 μM) administration. Left, actual 
luminescence recordings. Middle, rhythms derived from luminescence 
recordings after subtracting baseline. Right, Period calculation for each 
dose. Each number represents the mean ± SEM of three independent 
experiments, with each bioluminescent recording performed in triplicate. 















Figure 12. PER2 and CRY1 protein stability after metformin and 
HL271 treatment in presence of CHX. (A and B) Measurement of V5-
tagged PER2 and FLAG-tagged CRY1 degradation after treatment with 
cycloheximide (30 μg/mL) plus DMSO (control), metformin (2 mM), HL271 
(10 μM), or HL271IA (10 μM). Transfection efficiency were normalized by 
GFP. Each number represents the mean ± SEM of three independent 
experiments, with each experiment performed in triplicate. Comparisons 
by one-way ANOVA, followed by Tukey’s test. *P < 0.05 and **P < 0.01 


















Figure 13. PER2 and CRY1 protein stability after metformin and 
HL271 treatment in presence of CHX and MG132. Stability of V5-
tagged PER2 and FLAG-tagged CRY1 protein treated with CHX (30 
μg/mL) plus MG132 (50 μM) in the presence of DMSO, metformin, HL271, 
or HL271IA. Each number represents the mean ± SEM of three 
independent experiments, with each experiment performed in triplicate. 
















Figure 14. Changes of daily food intake, body weight, glucose and 
insulin level in mice treated with either metformin or HL271. (A) Daily 
food intake over 4 weeks in mice fed a normal diet (ND) or high-fat diet 
(HFD). Diet-induced obese mice were orally administered drinking water, 
metformin (400 mg/kg), or HL271 (10 and 30 mg/kg) at 09:30 every day 
for 4 weeks. (B) Measurements of whole body weights. Blood was 
collected from the tail veins of mice after a 12 h fast at baseline and after 
2 and 4 weeks. Blood samples were collected at the first day of drug 
injection (0 weeks), in the middle (2 weeks), and on the last (4 weeks) day 
following drug administration. Glucose and insulin concentrations were 
measured. The mean ± SEM for each group of ten mice is shown. Results 
compared by one-way ANOVA, followed by Tukey’s test. *P < 0.05 and 
















Figure 15. Effects of metformin and HL271 on liver G6pase and Pck1 
mRNA expression. (A and B) HepG2 cells were treated with DMSO 
(control), metformin (2 mM), or HL271 (10 μM). After 4 h, the cells were 
collected, and mRNA was extracted and analyzed by real-time RT-PCR 
for expression of (A) hG6pase and (B) hPck1 mRNA levels. Values shown 
are the mean ± SEM of two independent experiments performed in 
triplicate. (C and D) Eight-week-old wild-type mice were intraperitoneally 
administered metformin (500 mg/kg) or HL271 (100 mg/kg) dissolved in 
saline. A liver sample was obtained every 6 h for 24 h, and mRNA was 
extracted and the levels of (C) G6pase and (D) Pck1 mRNAs were 
analyzed by real-time PCR. The level of each cDNA was normalized 
relative to that of GAPDH. Results were compared by one-way ANOVA, 


















Figure 16. Total body fat mass changes. Total body fat was measured 
before treatment (0 weeks) and after 2 and 4 weeks of drug administration. 
Metformin (400 mg/kg) and HL271 (10 and 30 mg/kg) were administered 
orally dissolved in drinking water. The mean ± SEM for each group of ten 
mice is shown. Results compared by one-way ANOVA, followed by 


















Figure 17. Changes of lipid metabolites between metformin or HL271 
treated mice. Epidermal fat, white adipose tissue (WAT), and brown 
adipose tissue (BAT) were removed and weighed to the closest 0.01 mg. 
Blood samples were collected, and total cholesterol, high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, 
and triglycerides were measured. Liver and gastrocnemius muscle were 
collected from each mouse, and triglyceride levels were measured. Each 
number represents the mean ± SEM for each group of ten mice. Results 















 In Chapter 1, I have compared the effects of metformin and a 
novel metformin-derived compound, HL271, on molecular circadian clock 
functions and glucose and lipid metabolism. HL271 was more potent than 
metformin in phosphorylating AMPK and at modifying circadian clock 
oscillators. However, HL271 differed from metformin in metabolic 
regulation, including body weight, blood glucose, and insulin levels and 
lipid metabolite content in HFD-induced obese mice. Thus, from the 
results, I demonstrated that although molecular effects of metformin and 
HL271 displayed similar effects, the net physiological effects of metformin 
and HL271 differ and possibly due to its systemic effects.  
 Circadian clock timing is tightly integrated, with daily metabolic 
cycles including glucose homeostasis. AMPK phosphorylation of CRY1 
provided direct evidence for the molecular connection between circadian 
clock timing and glucose homeostasis (Lamia et al., 2009). In addition, 
CRY1 can modulate gluconeogenesis by inhibiting glucagon mediated 
cAMP-PKA signaling (Zhang et al., 2010) and by interfering with 
glucocorticoid receptors (Lamia et al., 2011). The faster CRY1 
degradation rate displayed by HL271 than by metformin may be due to 
the increased phosphorylation of AMPK by HL271. Therefore, the system-
wide difference between HL271 and metformin may be affected by the 
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stability of cryptochrome, which is important for maintaining circadian 
clock oscillation and glucose homeostasis.  
 The glucose-lowering and insulin-sensitizing effects of metformin 
were shown to involve the AMPK signaling pathway (Pernicova and 
Korbonits, 2014; Fortez et al., 2014). Net glucose lowering may be 
achieved by either an AMPK-dependent or AMPK-independent pathway 
(Quinn et al., 2013). In the former, metformin can lower the blood-glucose 
level by initiating the phosphorylation of AMPK, increasing the activity of 
insulin receptor substrate-2 (IRS-2), and thereby inducing the 
translocation of glucose transporters (Gunton et al., 2003). Metformin 
activation of AMPK can also inhibit fatty acid synthesis and lipogenesis 
by suppressing acetyl-CoA carboxylase (ACC) activity (Zhou et al., 2001; 
Fullerton et al., 2013). Even in the absence of AMPK, however, metformin 
can lower blood-glucose concentrations by rapidly inhibiting glucagon-
stimulated, cAMP-PKA-CREB-mediated gluconeogenesis (Fortez et al., 
2010). In addition, this AMPK-independent action of metformin causes the 
depletion of cAMP, affecting the expression of gluconeogenic genes such 
as G6pase and Pck1, by repressing transcription induced by cAMP-
responsive element binding protein (CREB-1) (Miller et al., 2013).  
 Altering the physiological concentrations of metformin can alter its 
effects (He et al., 2015). For example, at supra-pharmacologic 
concentrations (~5 mM), metformin inhibited mitochondrial respiratory 
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chain complex 1 in hepatocytes, leading to an increase in the AMP/ATP 
ratio and altering AMPK activation (El-Mir et al., 2000). A metformin 
concentration ≥2 mM was also required to suppress gluconeogenesis and 
to increase the AMP/ATP ratio (Fortez et al., 2010). However, at 
therapeutic concentrations in hepatocytes (40~70 μM), metformin was 
able to suppress gluconeogenesis by suppressing the expression of 
cAMP-stimulated gluconeogenic genes, reducing glucose production 
without affecting mitochondrial respiratory chain 1 (Cao et al., 2014). In 
addition, oral administration of a therapeutic concentration of metformin 
(50 mg/kg), either acutely or chronically, inhibited mitochondrial 
glycerophosphate dehydrogenase (mGDP), increasing cytosolic NADH 
and inhibiting lactate and glycerol functions, resulting in reduced glucose 
production (Madiraju et al., 2014). Taken together, the differences 
between metformin and HL271 may be caused by concentration-
dependent AMPK action and/or a direct or indirect effect of AMPK on 
multiple target tissues systematically influencing glucose and lipid 
metabolism.  
 Abundant clinical evidence indicates that the secondary effect of 
metformin can reduce the rates of various cancers, suggesting that 
metformin has anticancer activity (Giovannucci et al., 2010; Evans et al., 
2005). The antitumor effects of metformin are mediated by reducing 
circulating insulin and insulin growth factor-1 (IGF-1) levels, inhibiting 
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downstream tyrosine kinase signaling including through the PI3K-Akt-
mTORC1 pathway (Shackelford et al., 2013; Inoki et al., 2003). Metformin 
was also shown to regulate the expression of c-MYC, insulin receptor 
substrate 1 (IRS-1), and hypoxia-inducible factor 1α (HIF-1α) (Blandino et 
al., 2012). Therefore, along with on-going clinical trials, studies on the 
mechanisms underlying the secondary effects of metformin on tumor 
formation and development are necessary for the repositioning of this 
drug (Quinn et al., 2014).  
 In conclusion, this study compared the effects of HL271 and 
metformin on circadian clock regulation, glucose homeostasis and lipid 
metabolism. Although HL271 and metformin phosphorylated AMPK and 
influenced circadian clock oscillations in a similar manner, the two had 









Systemic role of omega-3 fatty acids on 





 Omega-3 fatty acids (FA) are known as essential fatty acids, 
which mammals require for normal development. Although omega-3 FA 
is known to elicit health benefits such as improved inflammatory system, 
retinal- and neural development, there are paucity of studies regarding 
the effects of omega-3 FA on circadian clock. In this chapter, I have 
utilized a unique omega-3 FA animal model, fat-1 transgenic (TG) mice, 
which converts omega-6 FA to omega-3 FA endogenously, to investigate 
effects of omega-3 FA on circadian oscillation. I have cross-mated fat-1 
TG mice with Per2:: luc KI mice and created fat-1/Per2::luc mice. First, I 
have investigated In vivo imaging analysis and fat-1/Per2:luc mice 
displayed enhanced Per2 expression in the peripheral tissues, including 
liver, kidney and submandibular gland. In fat-1 TG mice, clock mRNA 
levels were elevated in liver and kidney, however, clock gene expression 
in the hypothalamus only displayed shifting of period.  Molecular 
analysis revealed that in fat-1 TG mice, the core clock gene, BMAL1 was 
highly sumoylated and ubiquitinated eliciting enhanced proteosomal-
mediated degradation and protein turnover. In accordance with the 
alteration of clock oscillation in the SCN, fat-1 TG mice displayed 
elongated period during free-running activities in constant darkness (DD) 
condition. Therefore, in present study I demonstrate that ubiquitous 
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actions of omega-3 FA elicit systematic influence on circadian clock 
oscillation.  




 Daily metabolic process is governed by circadian clock system. 
Self-sustainable circadian clock is synchronized by the neuronal and 
hormonal signals from suprachaismatic nucleus (SCN) residing in the 
hypothalamic nucleus (Asher and Schibler et al., 2011; Eckel-Mahan and 
Sassione-Corsi, 2013). However, the environmental factors such as daily 
food intake, exercise, and behavioral activity can also synchronize 
peripheral clocks away from signaling factors from SCN. The molecular 
circadian clock is composed of two transcriptional- and translational-
feedback loops (Brown et al., 2012; Saini et al., 2011). The core loop 
consists of circadian locomoter output cycles kaput (CLOCK) and brain 
and muscle Arnt-like-1 (BMAL1) forming a heterodimer and initiating 
transcription of Periods (Per1-3) and Cryptochromes (Cry1 and Cry2) in 
the nucleus (Crane and Young, 2014). Following post-translational 
modifications, PERs and CRYs binds to each other and translocate back 
into the nucleus to repress CLOCK::BMAL1 heterodimer binding to its 
own promoter, eliciting a negative-feedback loop. To fine tune this 
feedback mechanism, nuclear receptor Rev-erbα and Rorα binds to their 
specific responsive element (RORE) in Bmal1 promoter to either repress 
or induce transcriptional process, respectively (Robles and Mann, 2013).  
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 High-fat diet (HFD) rich in saturated fatty acids (SFA), are known 
to disrupt circadian clock system by altering core clock gene expression 
and clock target genes in metabolic homeostasis (Kohsaka et al., 2007). 
Palmitic acid is most abundant form of SFA found in major body 
component and excessive palmitic acid leads to increase risk of 
developing cardiovascular disease, obesity and metabolic syndrome 
(Tahara et al., 2013). In circadian clock system, palmitic acid is known to 
destabilize circadian clock by either increasing expression of Bmal1 and 
Clock or decreasing Per2 and Rev-erbα mRNA transcripts in 
hypothalamic neuronal cells (Fick et al., 2011). Unlike SFA, 
polyunsaturated fatty acids (PUFA) containing more than one double 
bond in their carbon-carbon bond, are known to have beneficial effects on 
health. PUFA, especially omega-3 FA, are known as an essential fatty 
acids, because mammals, including humans, cannot synthesize them and 
can only obtain from diet. And in class of omega-3 FA, docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA) plays an important role in 
normal development, signal transduction and also is an important source 
of fuel (Hainault et al., 1993; Clarke SD., 2000). Despite the beneficial 
effects of omega-3 FA on normal metabolism and development, there are 
pittance amount of studies of its effects on circadian clock system.  
 In previous studies, investigating the effects of omega-3 FA on 
circadian clock consisted of external treatment of DHA or EPA. One study 
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have utilized the immortalized hypothalamic neuronal cell model, 
mHypoE-37, and investigated effects of omega-3 FA on transcriptional 
expression of circadian clock genes (Greco et al., 2014). And others have 
utilized dietary supplementation method to deliver DHA or EPA to 
investigate effects of omega-3 FA on circadian clock in vivo (Furutani et 
al., 2015). However, application of DHA or EPA abundant fish oil or diet 
consisting of highly concentrated omega-3 FA, may hold experimental 
consequences. For instance, PUFA is highly unstable and prone to 
oxidation which dietary supplementation of omega-3 fatty acids to animals 
may provide many variables potentially leading to confounding effects. In 
addition, equivalent delivery of omega-3 FA supplementation would be 
difficult for each animals, since individual variance in feeding and 
digestion cannot be controlled.  
 To overcome this experimental dilemma, Kang and colleagues 
have recently engineered a transgenic (TG) mice that can endogenously 
produce omega-3 fatty acid by inserting modified fat-1 gene from 
Caenorhabditis elegans, which encodes n-3 desaturase enzyme 
responsible for conversion of omega-6 FA to omega-3 FA (Kang et al., 
2004). Fat-1 TG mice displayed high level of omega-3 FA in most of the 
tissues and reduction of omega-6 FA when fed with normal diet in 
absence of dietary omega-3 FA, while displaying normal development and 
healthy phenotype (Kang et al., 2001).  This led to novel murine model 
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to study effects of omega-3 FA on various disease and cancer models. 
Recent researches demonstrated that in fat-1 TG mice prostaglandin E3 
(PGE3) level was increased resulting reduced melanoma formation (Xia 
et al., 2006), prevented age-related glucose metabolic syndromes 
(Romanatto et al., 2014), and also observed enhanced dendritic spine 
density and neurogenesis leading improved spatial learning tasks (He et 
al., 2009). Although fat-1 TG mice has been utilized as murine model to 
investigate influence of omega-3 FA in various studies, there are scarce 
amount of research involving its effects on circadian rhythm.  
 In the present study, I have investigated the underlying 
mechanism of omega-3 fatty acids on circadian clock oscillation by 
utilizing fat-1 TG mice which can endogenously convert omega-6 FA to 




Materials and methods 
Animals and locomoter activity 
 Fat-1 transgenic mice were gifted kindly provided by Dr. Lim Kyu 
(Chungnam National University). Fat-1 TG mice mixed background of 
C57/BL6J were cross-mated with Homozygous Per2::luc KI mice to 
generate fat-1/Per2::luc KI mice. All mice were raised in a sound-proof 
isolated room with a constant temperature (22-23℃) and humidity (50 ± 
10%). Lights were on at 08:00 AM and off at 20:00 PM (L:D=12 h:12 h) 
light intensity of 100-150 lux at cage level and provided with standard diet. 
Mice were housed with a wood-chip bedding (North Eastern Products 
Corporation, Warrenburg, NY). All mice experiments were carried out by 
the guidelines of the Laboratory Animal Center at Seoul National 
University and Daegu Gyeongbuk Institute of Science and Technology. 
 
In vivo imaging and analysis 
 C57/BL6J based male fat-1/Per2::luc KI and Per2::luc KI mice 
were dilapidated dorsal and ventral side to monitor organ 
bioluminescence. Mice were intraperitoneally [i.p] injected with 15 mg/kg 
D-luciferin potassium salt (Promega) dissolved in phosphate-buffer saline 
(PBS) under isofluorane anesthesia (Mylan Inc.) with mixture of oxygen. 
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After 8 to 10 minutes after D-luciferin injection mice were subjected to 
luminescence image acquisition by an in vivo imaging system (IVIS 
Kinetics; Caliper Life Sciences). All bioluminescence data were 
automatically calculated by Living Image 4.4 software (Caliper Life 
Sciences). Briefly, for each organ photon counts were measured same 
shape and size of the region of interest (ROI) at indicated times.  
 
Cell Culture 
 Wild type (WT), Per2::luc KI, fat-1 and fat-1/Per2::luc KI mouse 
embryonic fibroblasts (MEFs) were generated as previously described 
(Bea et al., 2001; Bunger et al., 2000; Todaro and Green. 1963a; Yoo et 
al., 2004). Primary cell line were maintained in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in a 
humidified atmosphere containing 5% CO2.  
 
Recording of real-time luminescence 
 Per2::luc KI and fat-1/Per2::luc KI MEFs were treated with1 μM 
dexamethasone 2 hr before recording. Before the start of recording, 
media were changed to normal culture media with 100 μM D-luciferin 
(Promega). Bioluminescence were measured for 1 min for each dish at 
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10 min interval by real-time luminescence monitoring device (Kronos-Dio; 
ATTO) at 35°C in a humidified chamber containing 5% CO2. Data were 
normalized by the average of the initial minimum value.   
 
Immunoblotting and immunoprecipitation 
 Tissues and cells were harvested as previously described (Lee et 
al., 2008). Briefly, cells and tissues were harvested in 
radioimmunoprecipiration assay (RIPA) buffer containing protease 
inhibitor cocktail (Roche). Equal amounts of total protein were incubated 
with 2 μg of anti-BMAL1 (Kwon et al., 2006) antibodies for 1.5 h at 4°C 
and then A/G-Sepharose bead slurry was added. For immnoblot analysis, 
target protein were detected by anti-BMAL1 generated in rabbit (Kwon et 
al., 2006), anti-SUMO2/3 (Abcam), anti-SUMO1 (Santa Cruz) antibodies. 
The immune complex were detected by ECL solution kit (Pierce).  
 
Quantitative real-time PCR 
 Total RNA from cells and tissues were extracted by TRIzol reagent 
(Invitrogen) according to manufacturer’s protocol. RNA was reverse-
transcribed reverse-transcribed using Moloney murine leukemia virus 
reverse transcriptase (Promega). Single stranded cDNA was PCR 
amplified by Chromo4 DNA Engine (BioRad), and expression was 
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quantified by SYBR green I analysis. The levels of expression of all genes 




 All statistical analyses were performed using GraphPad PRISM    
software (GraphPad Prism Software Inc.). Between-group comparisons 
were assessed by one-way ANOVA, followed by post-hoc Tukey’s test. 
All values are expressed as the mean ± SEM, with statistical significance 






Per2 expression is elevated in kidney, liver, and sub mandibular 
gland of fat-1 TG mice 
 To investigate and visualize clock gene expression in fat-1 TG 
mice in vivo, I have cross-mated with Per2::luc KI mice, which 
endogenous mPer2 gene is fused with luciferase at the 3’ end, posing 
PER2::LUC fusion protein (Yoo et al., 2004). Minutes after luciferin 
injection I have imaged bioluminescence of Per2::luc, as a positive control, 
and fat-1/Per2::luc mice in either dorsal or ventral position. In dorsal 
position we were able to visualize Per2 expression from kidney where at 
ZT 12 and ZT 18 fat-1/Per2::luc mice displayed significant increase of 
luminescence signal as compared to Per2::luc mice (Fig. 18 A up and B 
left). In ventral position, luminescence signals from liver and sub 
mandibular gland also showed significant induced expression of Per2 at 
ZT 12 and ZT 18 in fat-1/Per2::luc mice (Fig. 18 A down and B middle and 
right). These results demonstrates that clock gene expression is generally 
elevated in peripheral tissues of fat-1 TG mice throughout 24 h period.  
 
Hypothalamic clock gene and neuropeptide expression in fat-1. 
 Since, only a certain peripheral organs can be visualized by in vivo 
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luminescence system, I investigated the clock gene and clock-controlled 
hypothalamic neuropeptide expression in hypothalamic region of fat-1 TG 
mice. First, I have monitored Per2 expression from SCN tissues of either 
Per2::luc or fat-1/Per2::luc mice (Fig. 19). Compared to elevated Per2 
expression in the peripheral tissues in fat-1 mice, the amplitude of Per2 
expression in the SCN were not elevated, however, oscillating period 
were significantly shifted close to ~26 h. The peak expression period of 
Bmal1 and Per1 mRNA transcripts were also shifted in fat-1 hypothalamic 
tissue, however amplitude of clock gene transcript levels were not 
elevated (Fig 20). Since fatty acids are known to influence hypothalamic 
neuropeptide regulating energy homeostasis, we have examined the level 
of orexigenic neuropeptides, Agouti-related protein (Agrp) and 
neuropeptide Y (NyP), and anorexigeneic neuropeptides, pro-
opiomelanocortin (POMC) and the cocain-and amphetamine-regulated 
transcript peptide (CART). In fat-1 TG mice, Agrp expression at CT 06 
were significantly elevated, however, Nyp, Pomc, and Cart expression at 
CT 06 and 18 were not changed as compared to wildtype (WT) mice (Fig. 
21) 
 
Clock gene expression in fat-1 liver and kidney 
 To further investigate the elevated clock gene expression in 
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peripheral tissues in fat-1 TG mice, I have monitored Per2 expression in 
the livers of Per2::luc and fat-1/Per2::luc TG mice. In accordance with the 
in vivo imaging results (Fig. 18), the amplitude of Per2 expression in the 
fat-1 TG mice liver tissue were significantly increased (Fig. 22). Following 
the results, clock gene transcripts from liver and kidney displayed 
elevated amplitude of expression throughout 24 h period (Fig. 23). In both 
liver and kidney, compared to Bmal1, Clock and Per1 expression, Rev-
erbα expression were not significantly elevated (Fig. 23). Interestingly, 
compared to Per2 expression in the SCN, period shifting were not present 
in liver and kidney.  
 
BMAL1 sumoylation and proteaosomal degradation is increased in 
fat-1 TG  
 To understand the enhanced clock gene expression in fat-1 TG 
mice, I have investigated the turnover process of core clock component, 
BMAL1. Since oscillating levels of BMAL1 controls the transcription and 
regulation of clock controlled genes, including Per2, I have questioned 
whether BMAL1 modifications were changed in fat-1 TG mice. First, I 
have investigate the stability of BMAL1, I have utilized WT and fat-1 
mouse embryonic fibroblast (MEF) cells and treated with cycloheximide 
(CHX), protein synthesis inhibitor. BMAL1 protein in fat-1 MEF rapidly 
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diminished, with an estimated half-life of ~2 h, whereas BMAL1 protein 
from WT MEF displayed estimated half-life of ~3 h (Fig. 24). To delineate 
the role of proteasome-dependent degradation of BMAL1, I have further 
treated WT and fat-1 MEF with MG132, 26S specific proteasome inhibitor 
in presence of CHX. In accordance with previous results, MG132 
treatment strongly stabilized BMAL1 protein in both WT and fat-1 MEFs, 
indicating that increased sumoylation of BMAL1 in fat-1 TG mice 
demonstrates the induced level of proteaosomal-dependent degradation 
pathway leading to its enhanced turnover as compared to WT.  
 
Modification of BMAL1 by SUMO and uniquitin in fat-1 MEFs 
 To elucidate the turnover of BMAL1 in fat-1 TG mice, I further 
investigated sequential modifications in the circadian regulation of clock 
gene transcription and analyzed BMAL1 modification by SUMO and 
ubiquitin during the period of maximal and minimal transcription activation 
in cellular compartments. First, I treated Per2::luc and fat-1/Per2::luc 
MEFs with dexamethasone (DEX) for cellular synchronization and 
monitored luciferase activities. Fat-1/Per2::luc MEF oscillation displayed 
increased amplitude of Per2 expression, however, length of period were 
not changed between fat-1/Per2::luc and Per2::luc MEF (Fig. 25A). And 
the proceeding maximal and minimal transcriptional expression state at 6 
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h and 18 h, respectively after DEX treatment.  Following the luciferase 
activity, I measured the amounts of modified BMAL1 by SUMO and 
ubiquitin in cytoplasm and nucleus (Fig 25B). The levels of both the 
sumoylated and ubiquitinated proteins were markedly higher in the 
transcriptionally active phase than in the inactive phase which were more 
prominent in the nucleus than in the cytoplasm. In addition, modified 
BMAL1 in fat-1  MEF displayed markedly higher sumoylation and 
ubiquitination in both cellular compartments as compared to WT MEF (Fig 
25B). Thus, this demonstrates that the sequential modification of BMAL1 
by SUMO and ubiquitin in fat-1 TG mice is highly elevated as compared 
to WT mice. ` 
 
Locomoter activity of wild type and fat-1 TG mice under 12:12 light-
dark (LD) cycle following constant darkness (DD) condition 
 Lastly, to find out the behavioral outcome of fat-1 TG mice, I have 
analyzed the locomoter activity of fat-1 TG mice. After 10 days of 12 h: 12 
h light and dark cycle conditioning, all WT and fat-1 TG mice went to 
constant dark condition to measure the endogenously generated free-
running period (FRP). As expected all WT mice displayed period length 
shorter than 24 h period averaging about 23.48 h (Fig 26A left). However, 
fat-1 TG mice displayed ~.51 h of period lengthening (p<0.001) close to 
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24 h of FRP (Fig. 26B). The total wheel revolution per day were not 
significantly different between the two groups, however FRP close to 24 
h in fat-1 mice demonstrates that it holds robust endogenously generated 












Figure 18. 24 h In vivo imaging of Per2::luc and fat-1/Per2::luc mice. 
(A) In vivo luminescence imaging of Per2::luc and fat-1/Per2::luc mice 6 
h interval throughout 24 hr period. Images were assessed simultaneously 
at each time point. The upper row displays the dorsal position 
representing images of kidney 8 mins after 15 mg/kg D-luciferin injection. 
The lower panel represents the images of submandibular gland and liver 
10 mins after D-luciferin injection. (B) Normalized photon counts of kidney, 
liver and submandibular gland (Sub Gla). y-axis represents the recent 
change of bioluminescence throughout 24 hr period after daily average 



















Figure 18. 24 h In vivo imaging of Per2::luc and fat-1/Per2::luc mice. 
(A) In vivo luminescence imaging of Per2::luc and fat-1/Per2::luc mice 6 
h interval throughout 24 hr period. Images were assessed simultaneously 
at each time point. The upper row displays the dorsal position 
representing images of kidney 8 mins after 15 mg/kg D-luciferin injection. 
The lower panel represents the images of submandibular gland and liver 
10 mins after D-luciferin injection. (B) Normalized photon counts of kidney, 
liver and submandibular gland (Sub Gla). y-axis represents the recent 
change of bioluminescence throughout 24 hr period after daily average 






















Figure 20. Comparison of clock gene expressions in the 
hypothalamus between WT and fat-1 TG. (A) mRNA levels of Bmal1, 
Clock, Per1 and Rev-erbα in hypothalamic tissues of fat-1 and WT mice. 
Each time point represents average of four individual mice Mean±SEM; 




















Figure 21. Hypothalamic neuropeptide expression between WT and 
fat-1 TG Time-specific alterations of mRNA levels in hypothalamic 
appetite-regulating neuropepties Nyp, Pomc, Agrp and Cart at CT06 and 



















Figure 22. Comparison of Per2 expression in fat-1 WT liver tissue 
culture. (A) Representative records of bioluminescence showing 
PER2::LUC and fat-1/PER2::LUC liver. Photon counts are plotted against 
the LD cycle of 24 hrs. Shown are 168 hrs, equivalent of 7 days of 
continuous explant culture recording. (B) Bar charts summarizing 
changes in average period and amplitude. Peak-to-peak intervals during 
indicated time in an explant were averaged, and the mean period ± SEM 

















Figure 23. Comparison of clock gene expressions in the liver and 
kidney between WT and fat-1 TG. fat-1 and WT mice were sacrificed at 
indicated times and liver and heart tissues were extracted for mRNA 
analysis. Bmal1, Clock, Per1 and Rev-erbα mRNA transcripts in (A) liver 


















Figure 24. BMAL1 stability in fat-1 TG mice liver. WT and fat-1 MEFs 
were either treated with cycloheximide (30 μg/ml) alone or together with 
MG132 (50 μM) for the indicated times. The level of BMAL1 was analyzed 
by immunoblotting with anti-BMAL1 antibodies and Actin was used as a 
loading control. Relative BMAL1 levels were quantified by densitometer 


















Figure 25. Temporal changes of BMAL1 sumoylation and 
ubiquitination in cytoplasm and nucleus. (A) Representative circadian 
bioluminescence generated from PER2::LUC and fat-1/PER2::LUC MEFs. 
Cells were synchronized by 1 μM dexamethasone (DEX) for 2 h, and 
expressions were monitored for 72 hrs. (B) Changes in the abundance of 
modified BMAL1 by SUMO2/3 and Ub in cytoplasmic and nuclear fraction 
were analyzed after 6 h and 18 h after 1 μM DEX synchronization. Cells 
were treated with MG132 (50 μM) for 1 h before the indicated times. 
Fractions were analyzed by immunoprecipitation with anti-BMAL1 



















Figure 26. Difference of free-running period  between WT and fat-1 
TG mice. (A) Recordings of wheel-running activity of >10 weeks old male 
WT and fat-1 TG mice entrained in LD cycle for 10 days following DD 
condition for 20 days. (B) Free-running periods (FRP) of each individual 
mice during DD (tau) condition were analyzed by Chi-square distribution 
and data represents mean±SEM of WT (n=6) and fat-1 TG (n=8) mice. (C) 
















 In the present study, I observed systemic effects of omega-3 FA 
on circadian clock system by utilizing fat-1 TG mouse. Fat-1 TG mouse 
displayed elevated clock gene expression in peripheral tissues including 
liver and kidney, and increased sumoylation and ubiquitination of core 
clock gene BMAL1, inducing its turnover. Although clock gene expression 
were not elevated in hypothalamic tissue, Per2 expression in the SCN 
and hypothalamic Bmal1 mRNA transcripts displayed shifting of period. 
The period shifting of clock gene in the hypothalamic tissue coincided with 
shifting of the free-running period which were close to ~24 h as WT mouse 
had period around ~23.48 h.  
 Fat-1 TG mouse constitutes a novel genetic model to study 
influence of omega-3 FA in circadian clock. Previous studies have utilized 
fat-1 TG mice to cross-breed with various established disease mouse 
model to investigate the influence of omega-3 FA on development and 
progression of disease (Kang et al., 2007). For example, Berquin and 
colleges have investigated genetic effects of omega-3 on prostate cancer 
by cross-mating fat-1 TG mice with prostate-specific Pten-knockout mice, 
a prostate cancer animal model, generating PtenP-/-fat-1T/- transgenic 
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mice (Berquin et al., 2007). PtenP-/-fat-1T/- transgenic mouse displayed 
reduced prostate cancer development and increased longevity as 
compared to Pten-knockout mouse (Berquin et al., 2007). In the present 
study, I have utilized well-established circadian clock Per2 gene 
expressing animal model, Per2::luc KI mouse (Yoo et al., 2004), to 
investigate influence of omega-3 FA on global Per2 expression in 
Per2::luc KI mouse crossed with fat-1 TG mouse, fat-1/Per2::luc. Clearly, 
our findings extends the previous observation of utilizing dietary 
supplementation of omega-3 FA on clock gene expression, and 
investigating fat-1/Per2::luc mouse allowed proper evaluation of effect of 
omega-3 FA on circadian clock gene expression. 
 Many studies have revealed that high fat diet (HFD) consisting 
large amount of saturated fatty acids disrupt circadian rhythm. HFD leads 
to desynchronization between systemic interactions of core clock and 
local clock regulation (Kohsaka et al., 2007), and also compromise 
molecular clock system residing in each local clocks. Treatment of 
palmitic acid to mHypoE-37, immortalized hypothalamic neuronal cell-line, 
significantly increased transcriptional expression of Bmal1, and also 
caused phase delay of 1.4 h in Bmal1 and Rev-erbα mRNA transcript 
levels (Greco et al., 2014). In addition to palmitic acid treatment, Greco 
and colleges demonstrated that DHA treatment also altered Bmal1 
expression by increasing period length and phase advance Bmal1 
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expression different from palmitic acid treatment (Greco et al., 2014). Our 
study also observed altered hypothalamic clock gene expression in fat-
1TG mice where Bmal1 expression displayed phase advance and shifting 
of Per2 expression in the SCN (Fig. 2). In addition, Furutani and colleges 
recently demonstrated that administration of tuna oil or soybean oil 
containing of DHA and EPA in modified dietary animal chow promoted 
restrictive feeding (RF) induced phase shift in liver clock (Furutani et al., 
2015). And mice fed with diet containing DHA and EPA displayed 
significant phase delay of liver clock and induced three-fold increase of 
Per2 mRNA expression in the liver 120 min after RF feeding (Furutani et 
al., 2015). In fat-1 TG mice, under normal condition provided with regular 
chow, I have also observed increased Per2 expression in both in vivo 
imaging (Fig. 1), liver explant cultures, and clock gene transcripts in liver 
and kidney tissue (Fig. 3). Therefore, results from my investigation clearly 
demonstrates that both SFA and PUFA, especially omega-3 FA, alters 
circadian gene expression, however they conduct distinct effects on 
systematic outcomes. 
 In particular, I revealed elevated clock gene expression in fat-1 TG 
mice consisted of elevated sumoylation and ubiquitination of BMAL1 (Fig. 
4 and Fig. 5). It has been reported that modification of BMAL1 by 
SUMO2/3 and ubiquitin is responsible for circadian transcription 
activation and degradation of CLOCK/BMAL1 heterodimer complex (Lee 
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et al., 2008). In fat-1 MEFs, I observed sequential abundance of 
sumoylated and ubiquitinated BMAL1 in cytoplasm and nucleus, mostly 
prominent modification of BMAL1 showing in the nucleus (Fig. 5B). 
Elevated dual modification of BMAL1 in fat-1 TG mice lead to increased 
degradation regulating stability of BMAL1 and its turnover (Fig. 4B). In 
accordance with previous study, treatment of MG132 stabilized BMAL1 
degradation demonstrating sumoylated and ubiquitinated BMAL1 
degradation in proteasome-dependent manner (Lee et al., 2008; Kwon et 
al., 2006). Therefore, from the molecular mechanistic study, I provided 
possible clues about enhanced clock gene expression involving presence 
of omega-3 FA.  
 In addition, I have observed that in DD condition followed by 12:12 
LD cycle entrainment, fat-1 TG mouse displayed lengthening of period 
close to ~24 h compared to WT mouse showing average period length of 
~23.48 h (Fig. 6). Period lengthening in fat-1 TG mosue under free-
running condition correlates with the shifting and elongated clock gene 
expression in the SCN (Fig. 2) which dictates SCN regulation of 
entrainment and free-running rhythms under DD condition (Reppert and 
Weaver., 2002). Similar results were achieved in αMUPA TG mouse 
encoding overexpression of urokinase-type plasminogen activator (uPA) 
in the brain (Miskin et al., 1990). Some characteristics of αMUPA mice 
display spontaneously eating ~25% less and live ~20% longer compare 
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to WT (FVB/N) mouse (Miskin and Masos, 1997’; Miskin et al., 2005). 
Similar to my observation of fat-1 TG mouse, αMUPA mouse exhibit 
higher amplitude in the circadian expression of the clock genes in the liver 
and also free-running period close to ~24 h in both 8 months and 18 
months old mice (Froy et al., 2006; Gutman et al., 2011; Tevy et al., 2013). 
Although I did not observe the longevity of fat-1 TG mice, correlation of 
enhanced clock gene expression and behavioral locomoter activity with 
αMUPA mice, fat-1 TG mice may exhibit longer life-span. And further 
studies are needed to clarify this issue.  
 The present study, I investigated effects of omega-3 FA on 
circadian clock system. And provide evidence for role of omega-3 FA on 
molecular circadian clock oscillation, and illustrate possible benefits of 
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생체시계가 대사기능에 미치는 영향에 관한 연구 
노한상 
 
 인간이 가지고 있는 생체시계는 주기적인 환경 변화에 적응을 
할 수 있도록 시신경교차핵에 존재하는 중추시계나 여러 조직에 존재
하는 말초시계에서 동일한 분자적인 조절을 하게 된다.  이러한 생체
시계의 분자적 조절은 주기적으로 낮과 밤에 일어나는 현상 외에도 
우리 몸에서 여러 가지의 생리적 작용에도 영향을 미친다. 그 중 생
체 시계는 우리 몸에서 일어나는 대사 작용에 분자 수준이나 개체 수
준에서 많은 영향을 주는 것으로 알려 져 있다.  
 AMP-activated protein kinase (AMPK)는 주된 에너지 센서로
써 몸에서 에너지 양이 줄어들게 되면 활성화되어 대사 조절이나 당 
조절을 통하여 에너지 양을 다시 높이는 작용을 한다. 활성화된 AMPK
는 이러한 작용 외에도 생체시계에 직접적인 영향을 준다. PER2나 
CRY1의 경우 활성화 된 AMPK로 인하여 인산화가 되어 세포 안에서 수
준이 저하되게 된다. 여러 가지의 생리적 현상과 대사 작용에 영향을 
미치는 AMPK는 비만이나 당뇨병 같은 대사 질환의 주된 표적으로 여
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러 약물들이 개발되었다. 이러한 약물 중 당뇨병 치료제로 알려진 메
트포민과 신규약물인 HL271이 어떻게 생체시계에 영향을 미치는지 알
아보았다. 기존에 알려진 메트포민의 작용기작을 바탕으로 신규약물
인 HL271의 작용기작을 연구한 결과 HL271은 메트포민 보나 매우 낮
은 농도에서 AMPK를 활성화 시키고 생체 시계 유전자인 PER2와 CRY1
의 번역 후 공정 과정을 촉진 시키는 것을 볼 수 있었다. 생리작용으
로 체내의 당 수준과 인슐린 정도를 측정해 보았을 때 메트포민과 
HL271은 다른 결과를 초래하는 것을 관찰 할 수 있었다. 메트포민의 
경우 당 생성에 직접적으로 작용하는 G6pase 나 Pck1의 수준을 24시
간을 주기로 간에서 억제하는 것을 알 수 있었지만 HL271의 경우 낮
추지 못하는 것을 볼 수 있었다. 그러므로 인하여 메트포민과 HL271
은 분자적으로 AMPK 활성화나 생체시계 유전자 조절에 비슷한 작용을 
보이지만 개체 수준에서는 AMPK의 하위 단계에서나 직접적으로 당 수
준을 조절하는 분자적 요소들에 다른 영향을 미치는 것을 시사한다.  
 체내의 지방 및 지방산은 우리 몸에서 중요한 에너지원으로 
사용된다. 그 중 불포화 지방산 중 필수 지방 요소의 경우 우리 몸에
서 자체적으로 만들 수 없고 섭식을 통하여 얻을 수 있다. 불포화 지
방산 중에서도 오메가-3의 경우 뇌 기능 및 정상적인 성장 발달에 매
우 중요한 인자로 알려 져 있다. 이렇게 중요한 역할을 하는 오메가-
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3를 섭식 외에 체내에서 자체적으로 만들 수 있는 유전자 변형 쥐인, 
Fat-1 TG를 활용하여 오메가-3가 생체 시계 작용에 어떠한 작용을 미
치는지 알아보았다.  
 Fat-1 TG와 생체 시계의 리포터 쥐로 유전자 변형된 
Per2::Luc KI을 교배하여 오메가-3가 중추시계와 말초시계에서 미치
는 작용을 실시간 발광 기법을 통하여 연구를 수행하였다. 그 결과 
Fat-1쥐의 중추시계는 보통 쥐보다 주기가 빠른 것을 목격할 수 있었
고 말초시계에서는 보다 높은 진폭으로 생체시계의 발진에 영향을 미
치는 것을 알 수 있었다. 분자적으로 생체시계의 핵심 유전자인 
BMAL1의 조절 기작을 연구 해본 결과 Fat-1 TG에서의 경우 BMAL1의 
수준이 세포질이나 핵내에서 보통 쥐보다 높은 수준으로 존재하는 것
을 확인할 수 있었고 BMAL1은 번역 후 과정 중 ubiquitination과 
sumoylation된 형상으로 존재하는 BMAL1이 상대적으로 많은 수준에서 
존재하는 것을 목격할 수 있었다. 그러므로 인하여 오메가-3는 중추
시계나 말초시계에서 각각 다른 작용을 보이지만 결론적으론 생체시
계의 핵심유전자인 BMAL1의 활성과 번역 후 공정 과정에 영향을 미침
으로써 주기의 변화나 진폭을 높이는 것임을 밝힐 수 있었다. 더불어 
오메가-3가 분자적으로 중추시계나 말초시계에서 미치는 영향을 행동
학적으로 분석 해본 결과 보통 생쥐의 경우 내제적인 시계가 평균적
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으로 약 23.5시간의 주기를 보이는 반면, Fat-1 TG의 경우 24시간에 
가까운 주기성을 보이는 것을 목격할 수 있었다. 이러한 결과를 예전
의 연구들과 비교해 보았을 때 Fat-1 TG에서 만들어 지는 오메가-3는 
생체시계를 보다 튼튼하고 강건하게 조절을 하는 것으로 판단된다. 
그러므로 본 연구를 통하여 생체시계와 대사 작용의 연관성과 조절 
작용을 한 층 더 알아낼 수 있었고 앞으로 생체시계와 오메가-3의 작








주요어: 일주기리듬, AMPK, 메트포민, HL271, 오메가-3, Fat-1 TG, 
Period2, Cryptochrome 1, Bmal1.  
학번: 2010-20313 
137 
 
